Clinical Characteristics and Management of Coronary Artery Perforations by Lemmert, M.E. (Miguel) et al.
Clinical Characteristics and Management of Coronary Artery
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Background-—Coronary artery perforation (CAP) is a potentially lethal complication of percutaneous coronary intervention. We
report on the incidence, clinical characteristics, and management of iatrogenic coronary perforations based on an 11-year single-
center experience.
Methods and Results-—From February 9, 2005, through November 20, 2016, 150 CAP cases were identiﬁed from our
percutaneous coronary intervention database of 21 212 procedures (0.71%). Mean age of CAP patients was 6611 years, and
62.7% were male. Treated lesion type was B2/C in 94.6%, and 31.3% were chronic total occlusions. Nonworkhorse guidewires were
applied in 74.3%. CAP types were Ellis type I in 2.9%, Ellis type II in 40.4%, Ellis type III in 54.8%, and Ellis type III cavity spilling in
1.9%. CAP treatment was conservative (including prolonged balloon inﬂation) in 73.3%. Covered stents, coiling, and fat
embolization were used in 24.0%, 0.7%, and 2.0%, respectively. Pericardiocentesis for tamponade was required for 72 patients
(48.0%), of whom 28 were initially unrecognized. Twelve patients (12.7%) required emergency cardiac surgery to alleviate
tamponade. Periprocedural myocardial infarction occurred in 34.0%, and in-hospital all-cause mortality was 8.0%. All-cause
mortality accrued to 10.7% at 30 days and 17.8% at 1 year.
Conclusions-—CAP is a rare complication of percutaneous coronary intervention, but morbidity and mortality are considerable.
Early recognition and adequate management are of paramount importance. ( J Am Heart Assoc. 2017;6:e007049. DOI: 10.
1161/JAHA.117.007049.)
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I atrogenic coronary artery perforation (CAP) is a rare butpotentially lethal complication of percutaneous coronary
intervention (PCI). The risk of CAP is associated with female
and older patients but also with complex coronary anatomy,
use of oversized balloons or stents, excessive postdilatation,
and use of atheroablative devices and hydrophilic guidewires.1
CAP risk is directly proportional to the complexity of the PCI
procedure. The incidence of CAP is 0.43% with PCI1 but rises
to 2.9% in chronic total occlusion interventions.2
The imminent lethal outcome of CAP stems from the
hemodynamic compromise of ensuing cardiac tamponade.
The most commonly used classiﬁcation scheme of CAP is
the Ellis classiﬁcation.3 It assesses the angiographic
severity and determines the risk of adverse events such
as emergent cardiac surgery, myocardial infarction, tam-
ponade, or death. Interventional cardiologists should be
able to recognize CAP and know available treatment
options. So far, treatment options are mostly described
as case reports, and the sporadic review articles may not
cover the entire armamentarium.4–6 Our objective was to
report our single-center experience with CAP in terms of
incidence, clinical characteristics, treatment options, and
outcome.
Methods
Study Design
This study was a single-center, retrospective analysis of the
overall prospective PCI database between February 9, 2005,
and November 20, 2016. During this period, a total of 150
cases of iatrogenic CAP occurred. The respective PCI
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procedures were subsequently analyzed. This study was
performed in accordance with the Declaration of Helsinki.
Because this is a retrospective analysis, the local medical
ethics committee waived the requirement to obtain informed
consent.
Baseline Characteristics
PCI indication, age, sex, the presence of multivessel
coronary artery disease, and kidney function were collected
in a dedicated database. Lesion characteristics were
obtained from the respective angiographic studies by
experienced reviewers and classiﬁed according to the
American College of Cardiology (ACC) and American Heart
Association (AHA) lesion classiﬁcation.7 CAPs were classiﬁed
using the Ellis classiﬁcation, which is based on the
angiographic appearance of the CAP: type I indicates
extraluminal crater without extravasation, type II indicates
pericardial or myocardial blush without contrast jet extrava-
sation, type III indicates contrast jet extravasation through
frank (≥1 mm) perforation, and type III cavity spilling (CS)
indicates contrast jet extravasation into an anatomic cavity
(eg, cardiac chamber or coronary sinus).3 A detailed
overview of the materials used during each PCI was
gathered by review of the original procedure reports. For
this analysis, the Balance Middle Weight (Abbott Laborato-
ries), Sion (Asahi Intecc), and the Pilot 50 (Abbott Labora-
tories) were considered workhorse guidewires, and all other
guidewires were considered nonworkhorse escalation wires.
Because there is a distinction between possible etiology and
treatment of proximal perforations (ie, those typically caused
by aggressive balloons or devices) and distal perforations (ie,
those typically caused by guidewire exits), the occurrence of
guidewire exits was registered. Preprocedural use of glyco-
protein 2b/3a inhibitors, protamine, predilatation, postdi-
latation, stenting, and atheroablative devices and use of the
largest balloon or stent size were registered.
End Point Deﬁnitions
The co–primary end points were pericardiocentesis to allevi-
ate (imminent) clinical tamponade, emergency cardiac surgery
for treatment of tamponade, secondary “bail-out” coronary
artery bypass grafting (ie, to treat the coronary artery disease,
instead of PCI), and in-hospital death. Periprocedural myocar-
dial infarction was deﬁned as a rise in cardiac markers 5 times
the upper limit of normal, according to the European Society
of Cardiology’s third universal deﬁnition.8 Thirty-day and 1-
year survival data for all patients were obtained from the
municipal civil registry, and general practitioners were con-
tacted for additional information if necessary.
Statistical Analyses
Descriptive analyses were performed using IBM SPSS Statis-
tics version 24.0. Continuous variables are presented as
meanSD. Categorical variables are expressed as percent-
ages. For comparison of categorical variables, the Pearson v2
test or Fisher exact test was used, as appropriate. All
statistical tests are 2-tailed, and P<0.05 is considered
statistically signiﬁcant. The authors take responsibility for
the integrity of the data and the accuracy of the analyses.
Results
During the study period, a total of 21 212 percutaneous
coronary procedures were performed including PCI, fractional
ﬂow reserve, intravascular ultrasound, and optical coherence
tomography procedures, of which 150 (0.71%) were compli-
cated by CAP. Baseline and procedural characteristics of the
CAP patients are shown in Table 1, and clinical outcomes are
shown in Table 2.
Baseline and Procedural Characteristics
Mean age of the CAP patients was 6611 years, and 62.7%
were male. Renal impairment was present in 18.5% of
patients, and multivessel disease was present in 53.7%.
Target lesions were classiﬁed as ACC/AHA type B2 or C in
94.6%, and angiographic calciﬁcations were present in 61.6%
of patients. Overall, 31.3% of the CAP cases involved chronic
total occlusions. Three cases of CAP occurred without a frank
PCI: CAP occurred in 1 patient who underwent analysis of the
perfusion of an intrapericardial glomus tumor, in 1 patient
during a fractional ﬂow reserve measurement, and in 1 patient
during intravascular ultrasound imaging.
Predilatation and stenting were performed in most patients
(67.6% and 75.3%), whereas rotablation and cutting balloons
were used in 4 patients (2.7%) and 1 patient (0.7%),
respectively. A nonworkhorse guidewire was used in 74.3%,
Clinical Perspective
What Is New?
• This is a detailed and comprehensive overview of a large-
volume, single-center experience with regard to the inci-
dence, characteristics, management, and outcome of iatro-
genic coronary artery perforations.
What Are the Clinical Implications?
• Iatrogenic coronary artery perforation is a rare but poten-
tially lethal complication of percutaneous coronary inter-
vention that requires prompt recognition and treatment.
• We provide an overview of contemporary treatment options.
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and guidewire exit was the underlying etiology of CAP in
61.5% of cases.
In 37 patients (24.7%), CAP was unrecognized during the
PCI procedure. For 9 patients, the available angiograms did
not allow proper application of the Ellis classiﬁcation. Among
the 104 patients in whom the CAP was visible during
angiography, most CAPs were Ellis types II (40.4%) and III
(54.8%). The immediate treatment in the catheterization
Table 1. Baseline and Procedural Characteristics of the CAP
Patients
Patient characteristic Result
Age, y 65.6 (10.7)
Male sex 62.7
Renal impairment (n=146) 18.5
Multivessel disease (n=149) 53.7
Indication for procedure
Stable angina 45.3
NSTE-ACS 28.7
STEMI 24.7
Ischemic heart failure 0.7
Analysis of intrapericardial glomus tumor 0.7
Treated vessel (n=141)
LAD 39.0
LCX 19.1
RCA 36.2
LMCA 1.4
SVG 4.3
Lesion type (n=147)
A 0.7
B1 3.4
B2 29.9
C 64.6
B2/C 94.6
Calcification (n=136) 61.6
CTO 31.3
FFR only 0.7
IVUS only 0.7
Procedure characteristics
Stenting 75.3
Use of nonworkhorse wire (n=140) 74.3
Predilatation (n=145) 67.6
Predilatation NC balloon (n=140) 20.7
Postdilatation (n=115) 39.1
Largest balloon/stent, mm (n=118) 3.16 (0.78)
Use of glycoprotein 2b/3a inhibitor 8.7
Use of protamine (n=146) 13.7
Rotablator 2.7
Burr size, mm 1.4 (0.1)
Cutting balloon 0.7
Wire exit (n=148) 61.5
CAP type (n=104)
Ellis I 2.9
Continued
Table 1. Continued
Patient characteristic Result
Ellis II 40.4
Ellis III 54.8
Ellis III-CS 1.9
CAP treatment on table
Unrecognized CAP 24.7
Conservative 41.3
Balloon 7.3
Covered stent(s) 24.0
Coils 0.7
Fat embolism 2.0
Figures are presented as percentages or as mean (SD), as appropriate. The numbers in
the table are based on the complete sample of CAP patients (n=150), unless indicated
otherwise. CAP indicates coronary artery perforation; CS, cavity spilling; CTO, chronic
total occlusion; FFR, fractional ﬂow reserve; IVUS, intravascular ultrasound; LAD, left
anterior descending coronary artery; LCX, left circumﬂex coronary artery; LMCA, left
main coronary artery; NC, non-complaint; NSTE-ACS, non–ST-segment–elevation acute
coronary syndrome; RCA, right coronary artery; STEMI, ST-segment–elevation myocardial
infarction, SVG, saphenous vein graft.
Table 2. Clinical Outcomes of the CAP Patients
In-hospital course Result, %
Tamponade treated by pericardiocentesis 48.0
Tamponade treated only by surgery 2.7
Pericardiocentesis after unrecognized CAP 75.7
Pericardiocentesis after initially conservative/balloon 32.9
Pericardiocentesis after covered stent 52.8
Pericardiocentesis after coils 100
Pericardiocentesis after fat embolism 0
Cardiac surgery 12.7
Periprocedural MI 34.0
“Bail-out” CABG 5.3
Death 8.0
Post-hospital course
30-d mortality (n=149) 10.7
1-y mortality (n=135) 17.8
CAP indicates coronary artery perforation; CABG, coronary artery bypass grafting; MI,
myocardial infarction.
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laboratory was most often conservative (73.3%), including use
of prolonged balloon inﬂation, which was performed in 7.3% of
patients. Placement of ≥1 covered stents was necessary in
24.0%. Among the patients with guidewire exit as the etiology
of the CAP, 32.0% had Ellis type III CAP and 1.1% were treated
with a covered stent; among the patients without guidewire
exit, 75.9% had Ellis type III CAP and 57.9% were treated with
a covered stent (both P<0.001, not shown in table). Coiling of
the coronary artery was performed in 1 patient (0.7%), and
autologous fat embolization was applied in 3 patients (2.0%).
Clinical Outcomes
Clinical tamponade occurred in 50.7% of CAP patients. The
tamponade was treated by pericardiocentesis in 48.0% of
cases. Late drainage for tamponade was required in one-third
of the patients with initial conservative management and half
of patients treated with a covered stent (Figure 1). Emergency
cardiac surgery to alleviate the tamponade was required in
12.7% of cases, with the tamponade being treated primarily by
cardiac surgery in 4 CAP patients (in 1 patient after initial
conservative therapy, in 1 patient after covered stent, and in 2
patients with initially unrecognized CAPs).
Periprocedural myocardial infarction was present in 34%,
and in 5.3% of patients, a bail-out coronary artery bypass
grafting was performed. The all-cause mortality rate of CAP
patients was 8.0% in hospital, 10.7% at 30 days, and 17.8% at
1 year. In-hospital and 1-year mortality rates were not
signiﬁcantly different in patients with and without guidewire
exit as the underlying etiology, but the 30 day-mortality rate
was signiﬁcantly higher in patients without a guidewire exit
(16.1% versus 5.5%; P=0.034, not shown in table). The
mortality rates per initial treatment modality are shown in
Figure 2.
Discussion
The CAP incidence of 0.71% in our population is in accordance
with large contemporary registries, in which CAP incidences
were 0.33%,9 0.22%,10 and 0.19%,11 respectively. CAP
incidence may be somewhat higher because of greater lesion
complexity in our procedures, reﬂected, for instance, by the
high prevalence of chronic total occlusion treatment of 31.3%
(compared with 21%,9 28.6%,10 and 18%11 in the aforemen-
tioned registries). In general, invasive imaging may guide
complex PCI strategy in terms of device selection including
rotational atherectomy and balloon selection. This may reduce
the incidence of CAP but needs further study.
CAP is associated with considerable morbidity and mor-
tality. In our CAP cohort, 30-day mortality was 10.7%. For the
remainder of the 1-year follow-up, the mortality rate was
comparable to the 7.1% 1-year mortality rate in the overall
cohort of patients undergoing PCI at our center during the
same time window.
Al-Lamee et al reported an in-hospital mortality rate of
14.8% among patients with an Ellis type III CAP.10 Without
Figure 1. Percentage of patients treated with pericardiocentesis after each CAP treatment. CAP indicates
coronary artery perforation; pt(s), patient(s).
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stratifying for Ellis type, the in-hospital mortality rate
described by Javaid et al was 16.7%.11 In comparison, our
mortality rates are somewhat lower and more in line with a
recent registry, in which the in-hospital, 30-day, and 1-year
mortality rates were 8%, 11%, and 15%, respectively.9 As
shown in Figure 2, the mortality rates in our cohort were
highest in patients initially treated with a covered stent.
Treatment Options
Similar to our cohort, Al-Lamee et al describe infrequent use
of coils in 1.8% of cases and a relatively frequent use of
covered stents in 46.4%. Acute pericardiocentesis was
performed in 28.6% of their patients.10 In the cohort of Javaid
et al, coils were used in 4.2% of cases, covered stents in
18.1% and tamponade occurred in 19.4%.11
Compared with those cohorts, tamponade and subsequent
treatment consisting of pericardiocentesis or surgery were
more frequent in our series. Need for pericardiocentesis after
an initially unrecognized CAP or initially conservative treat-
ment was substantial, but the in-hospital mortality rates of
these patients—respectively, 5.4% and 6.8%—are lower than
the rates described by Al-Lamee et al and Javaid et al.10,11
This might imply earlier recognition and treatment of
tamponade in our cohort, which could translate to improved
acute survival. As shown in Figure 1, in 19 of the 36 patients
who were initially treated with a covered stent, pericardio-
centesis still became necessary. Unfortunately, we do not
have detailed documentation of the reasons for lack of
success after covered stent placement. In theory, some
reasons are conceivable: (1) incomplete coverage of the
perforated area, which might not be immediately evident after
placement of the covered stent (geographical miss); (2) devel-
opment of tamponade already, before but only clinically
evident after the placement of the covered stent; or
(3) incomplete apposition or underexpansion of the covered
stent.
Our data underscore the importance of systematic
echocardiographic monitoring to screen for pericardial effu-
sion and fast pericardiocentesis in case of tamponade.
Echocardiography should be repeated during the next
24 hours to rule out late tamponade, as described by Ellis
in 19943 and as illustrated in our cohort by the need for
pericardiocentesis in 32.9% of patients after an initial
conservative approach and in 52.8% of patients after place-
ment of a covered stent. When further actions are required,
CAP location and severity play decisive roles. In general,
proximal CAPs require covered stents or surgical repair, and
distal CAPs caused by wire exits can be treated with
embolization therapies including coils, microspheres, throm-
bin, and autologous fat or blood.
Universal Treatment Approach
Prolonged proximal balloon inﬂation (1:1 balloon:vessel size)
allows the operator to gain time, and multiple runs of
prolonged balloon inﬂation may be required. Intravenous
anticoagulant and antiplatelet therapy need to be discontin-
ued, and activated clotting time should be corrected with
protamine. If glycoprotein IIb/IIIa antagonists were
Figure 2. Mortality rates after each CAP treatment. CAP indicates coronary artery perforation; pt(s),
patient(s).
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administered, platelet transfusions may be reasonable. Most
Ellis type I and II CAPs can be treated with this minimal,
relatively conservative approach, especially more distal CAPs
caused by guidewire exits. Rapidly increasing pericardial
effusion and frank tamponade justify early pericardial
drainage.
Covered Stents
Originally designed to tackle in-stent restenosis,12,13 cov-
ered stents have an important role as bail-out treatment of
CAP, especially when located in the proximal vessel
segments with a diameter ≥2.75 mm, that is, more
proximal CAPs that are more likely caused by oversized
or aggressive use of balloons or devices. The main
objective of a covered stent is to seal the perforation with
a layer impermeable to blood. Table 3 shows currently
available covered stents. Stents covered with the biocom-
patible polymer PTFE (polytetraﬂuoroethylene) are the most
commonly used. Although survival after CAP has improved
and the need for emergent cardiac surgery has decreased
since the application of covered stents, there are intrinsic
limitations.14 First, all covered stents carry the inherent risk
of side branch occlusion; therefore, when a major side
branch is likely to be occluded, an alternative treatment
option, such as cardiac surgery, must be considered.
Second, there are concerns about late thrombogenicity of
PTFE-covered stents15 that might be overcome with
prolonged dual-antiplatelet therapy.16 Newer generation
covered stents contain graft material made from autologous
veins or equine pericardium to improve stent ﬂexibility and
decrease thrombogenicity.17–19
Coiling
Coils are permanent metallic (stainless steel or platinum)
agents with a wired structure of synthetic wool or Dacron
ﬁbers and thrombogenic properties. Coils can be delivered
through normal guide catheters or through microcatheters for
distal and more precise placement. The chosen coil size
should be larger than the target vessel size to ensure
complete vessel adherence and embolization. Coils that are
too large may inadvertently be deployed too proximally, and
coils that are too small may migrate too distally. Coils are
generally used for CAPs in more distal and smaller caliber
segments.5
Microspheres
Microspheres are spherical, hydrophilic, nonabsorbable par-
ticles that come in sizes ranging from 1 to 1500 lm and that
can be delivered through a microcatheter. The variety of sizes
makes microspheres suitable for embolization of a wide range
of vessels. Similar to coils, microspheres are chieﬂy applied in
peripheral vasculature, for instance, to occlude blood supply
of vascularized tumors or arteriovenous malformations.
Recently, microsphere embolization was described as an
alternative to alcohol in percutaneous transluminal septal
myocardial ablation as treatment of hypertrophic cardiomy-
opathy.20 Shortly thereafter, successful treatment of CAP
using microspheres was described.21,22 Although the evi-
dence supporting the safety and efﬁcacy of microspheres in
the management of CAP is still scarce, microspheres allow
more precise sealing of the perforation, limiting collateral
damage.
Table 3. Covered Stents
Name Graftmaster Jostent ProGraft Autologous Vein Over and Under
Manufacturer Abbott Vascular concepts Assembled by operator on metal
stent
ITGI Medical
Stent material Stainless steel (BMS) BMS Any stent Stainless steel (BMS)
Graft material Expandable PTFE single layer Expandable PTFE Vein from patient Equine pericardium
Minimum guide
catheter
≥6F (2.8–4.0 mm)
≥7F (4.5–4.8 mm)
≥6F (3.0–3.5 mm)
≥7F (recommended)
≥6F (2.5–3.5 mm)
≥7F (3.5–4.0 mm)
Length, mm 16, 19, 26 15, 20, 25, 30 13, 18, 23, 27
Diameter, mm (max) 2.8 (3.25)
3.5 (3.95)
4.0 (4.48)
4.5 (4.94)
4.8 (5.29)
3.0 (3.14)
3.5 (3.61)
4.0 (4.04)
4.5 (4.60)
2.5
3.0
3.5
4.0
Disadvantages High crossing profile and low
flexibility
High crossing profile and low
flexibility
Requires time and expertise to
assemble
Requires washing before
use
BMS indicates bare metal stent; PTFE, polytetraﬂuoroethylene.
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Thrombin Injection
Thrombin is a potent platelet activator, and it directly
promotes the formation of ﬁbrin clots. Local and precise
administration of thrombin containing solutions and a com-
mercially available glue containing thrombin and ﬁbrinogen,
administered through a microcatheter or an over-the-wire
balloon, have been described to seal distal perforations.23–26
Autologous Blood Clots
Contrary to the methods mentioned, autologous blood is
universally available and biocompatible in every patient.
Furthermore, it does not entail additional costs. The success-
ful sealing of CAPs with autologous blood clots suspended in
contrast media and saline has been described.27,28 One case
report describes normal blood ﬂow in the treated coronary
branch 6 months later, owing to clot lysis after sealing of the
perforation.28
Fat Embolization
Autologous subcutaneous fat has the same advantages of
universal availability and biocompatibility without additional
costs. Fat particles can form a physical barrier to leakage
from blood, but they also activate the coagulation pathway,
thereby sealing the coronary perforation. To obtain radiopac-
ity, the particles must either be dipped into contrast or be
delivered using contrast. Delivery of fat particles as CAP
treatment was performed in our population and has been
described previously.29,30
Conclusion
CAP is a rare complication of PCI, but it is associated with
high morbidity and mortality. Hemodynamic status, CAP
location, the individual coronary anatomy, the amount of
myocardium at risk, and a patient’s ability to undergo cardiac
surgery determine the treatment strategy.
Disclosures
None.
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